LEXX
Lexaria Bioscience Corp.
NASDAQ · Healthcare · Biotechnology · CA
$4.07
+0.99%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$4.12
From 52W high−79.75%
Volume32270.00
Market cap$8.57M
P/E (TTM)—
P/S (TTM)44.2x
Div yield—
Key dataNov 4, 2026
Open
$4.12
From 52W high
−79.75%
Volume
32270.00
Market cap
$8.57M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
56.8
MomentumView details →
1D Return
+0.99%
YTD Return
−55.57%
SummaryUpdated May 1, 2026
Lexaria Bioscience Corp. (NASDAQ:LEXX) is a Canadian biotechnology company founded in 2004 and headquartered in Kelowna, British Columbia. The company went public on NASDAQ in January 2021. Lexaria operates as a drug delivery technology company focused on developing and commercializing its proprietary DehydraTECH platform, which enhances the oral absorption of active pharmaceutical ingredients. The company maintains an in-house research laboratory and holds an intellectual property portfolio comprising 23 granted patents and approximately 50 pending patents worldwide.
Similar companies
Latest newsMore news →
Lexaria Bioscience entered into an agreement with an unnamed pharmaceutical company to investigate its DehydraTECH technology with one or more of the company's proprietary molecules.8h agoLexaria Bioscience Corp. received new patents in the United States, Canada, and Europe covering treatments for epilepsy, diabetes, and hypertension.7d ago